HScore for Reactive Hemophagocytic Syndrome

Why use it

Reactive HPS is a life-threatening inflammatory syndrome that is frequently underdiagnosed due to its heterogeneous presentation and the need for invasive bone marrow biopsy. The HScore provides a non-invasive, quantitative probability estimate that aids clinical decision-making — particularly in critically ill patients where early treatment with immunosuppression (steroids, IVIG, cyclosporine, etoposide) can be life-saving. A score ≥169 carries >93% probability of HPS, supporting empirical treatment initiation pending histological confirmation.

About

The HScore is a validated clinical scoring system developed by Fardet and colleagues to estimate the probability of reactive hemophagocytic syndrome (HPS), also referred to as reactive hemophagocytic lymphohistiocytosis (rHLH) or secondary HLH. Published in 2014, the HScore was derived from a multicenter cohort and uses 9 clinical, biological, and histological parameters that reflect the core pathophysiology of HPS: hyperinflammation, cytopenias, hepatosplenomegaly, hypertriglyceridemia, hypofibrinogenemia, extreme hyperferritinemia, elevated transaminases, fever, and known immunosuppression. Unlike the HLH-2004 diagnostic criteria (which are primarily designed for primary/genetic HLH in children), the HScore was specifically validated for REACTIVE (secondary/acquired) HPS in adults. Each parameter is assigned a weighted score, and the total HScore correlates with the probability of HPS diagnosis. The tool allows serial monitoring as the clinical picture evolves.

When to use

• Any patient with unexplained fever, cytopenias, splenomegaly, and marked hyperferritinemia (>500 ng/mL)
• Critically ill patients with suspected macrophage activation syndrome (MAS) in the context of rheumatological disease, infection, or malignancy
• Patients with ferritin >10,000 ng/mL — extreme hyperferritinemia is a major red flag for HPS
• Before initiating or escalating immunosuppressive therapy for suspected reactive HLH
• Serial monitoring of disease probability as laboratory results evolve over 24–72h
• Adults with newly diagnosed autoimmune disease or lymphoma presenting with systemic inflammatory syndrome

Formula

Pearls & pitfalls

• Ferritin >10,000 ng/mL is highly sensitive for HPS — always check ferritin in any critically ill patient with unexplained multiorgan dysfunction.
• The HScore is validated for REACTIVE/SECONDARY HPS in adults — it is NOT a validated diagnostic tool for primary (genetic) HLH in children.
• Bone marrow hemophagocytosis (item 9) adds 35 points — its absence does NOT exclude HPS, as sensitivity of a single bone marrow sample is only 50–70%.
• Known immunosuppression (item 1) includes HIV, organ transplant, corticosteroids, biological agents, or malignancy — it adds 18 points and provides clinical context.
• Elevated AST (item 8) reflects hepatic involvement — a characteristic feature of HPS alongside direct histological hemophagocytosis.
• Hypofibrinogenemia (fibrinogen ≤250 mg/dL) is a marker of consumptive coagulopathy from macrophage activation and is a key diagnostic feature.
• Hypertriglyceridemia (>354 mg/dL) is caused by inhibition of lipoprotein lipase by interferon-gamma — one of the most specific laboratory findings for HPS.
• Treatment of HPS without identifying and treating the underlying TRIGGER (lymphoma, EBV, CMV, autoimmune disease) leads to relapse — a comprehensive trigger workup is essential.
• The HScore can be recalculated serially — rapid improvement in score after treatment initiation supports HPS diagnosis; lack of improvement suggests alternative diagnosis or refractory disease.

Next steps

HScore <90 (<1% probability): HPS unlikely. Continue workup for alternative diagnoses. HScore 90–129 (1–13%): Low-moderate probability. Pursue bone marrow biopsy and additional workup. Do not initiate empirical HPS treatment. HScore 130–149 (26–41%): Moderate probability. Expedited bone marrow biopsy. Consider rheumatology/haematology consultation. HScore 150–169 (53–79%): High probability. Bone marrow biopsy should be performed urgently. Begin treatment discussion — steroids (dexamethasone) ± IVIG depending on clinical severity. HScore >169 (>93%): Very high probability of HPS. Begin immunosuppressive treatment empirically if clinical urgency dictates. Cyclosporine, etoposide, and/or IVIG may be required for refractory cases. Treat underlying trigger (infection, malignancy, autoimmune disease).

Evidence

Fardet L et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613-2620. PMID:24782338. Derivation cohort: 312 patients (162 HPS, 150 controls). Validation in 5 independent cohorts. AUROC 0.92. At threshold score of 169: sensitivity 93%, specificity 86%. Score ≥169 associated with >93% probability of HPS. Widely adopted in European and North American clinical practice.

References

1. Fardet L et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613-2620. — link
2. La Rosée P et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465-2477. — link
3. Henter JI et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131. — link